Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, July 27, 2020

NIH High-Risk, High-Reward Research Programs

NIH has four high-risk, high-reward research programs.  Research may be basic, translational, or clinical. The primary requirements

are that the research be highly innovative and have the potential for unusually broad impact.  None of these programs requires

preliminary data or a detailed experimental plan. What is required a great idea and compelling logic of how it might be achieved.

The Pioneer Award Program: for investigators at any career stage who have a record of unusually innovative research and who

propose pioneering ideas going forward. (Application receipt date of September 11, 2020.)

The New Innovator Award: for Early Stage Investigators (those within ten years of receipt of their terminal research degree or

completion of their clinical training) who propose unusually innovative and impactful research. (Application receipt date of

August 21, 2020.)

The Transformative Research Awards: for individuals (single Principal Investigator) or teams (multiple Principal Investigators)

who propose unconventional, potentially groundbreaking research projects with flexible budgets. (Application receipt date of

September 30, 2020.)

The Early Independence Awards: for exceptional junior scientists who wish to “skip the post-doc” to launch independent research

careers (only up to two applications per institution are allowed). (Application receipt date of September 4, 2020.)

See attached flyer for additional information.



NIH Protecting U.S. Biomedical Intellectual Innovation:  NIH and the biomedical research enterprise have a long history of

International collaborations with rules of engagement that allow science to advance while also protecting intellectual capital and

proprietary information of the participating countries. These rules of engagement also are designed to limit bias in the design,

conduct, and reporting of NIH-supported research. This website describes actions that NIH, institutions, and researchers can

take to protect U.S. biomedical intellectual innovation. For Examples of What to Disclose to NIH about Senior/Key Personnel on

Applications and Awards please see the attached document.  URL: of What to Disclose to NIH about Senior.docx?ver=2020-07-20-071838-987





The primary objective of the PHF Bridge Grant program is to provide funding to enhance OUHSC faculty competitiveness for extramural

funding. OUHSC Principal Investigators who have submitted an extramural application that was scored but not funded within the past 18

months and is requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs and

received a review that ranks applications and provides critiques are eligible.  This program can provide funding for up to $75,000 for

one year. Guidelines and Application Form is attached or can be found at:

URL: Grant Guidelines - 07.06.2020.docx?ver=2020-07-13-101339-100


NIH Posts COVID-19 Guidance for Preparing Fall 2020 Applications
The NIH Office of the Director’s released new guidance for preparing grant applications with fall 2020 due dates, the earliest being Sept. 25.

The guidance states that NIH grant applications should not include COVID-19 contingency plans and that reviewers will be instructed to

disregard situations due to COVID-19.  For additional information go to:



OCAST – the Health Research Proposal board does not meet until August 11, 2020.   We will not know anything about who will be funded

until after August 11th.



The Stephenson Cancer Center is pleased to announce the American Cancer Society – Institutional Research Grant (ACS-IRG) Pilot

Project grant funded by the American Cancer Society. The ACS-IRG is a unique source of funding entrusted to SCC that provides seed

money for young investigators interested in cancer-related research. While the grant is administered at SCC, eligible applicants at OUHSC

Tulsa, OU Norman and OU-Tulsa may apply.

Applicants may request up to $50,000 for a 12-month project that:

  • Is relevant to the goals of the ACS and is cancer-related
  • Has high scientific merit
  • Has potential to be leveraged for future extramural funding

Only full time Assistant Professors within six years of their initial faculty appointment and with no active peer-reviewed funding from national

funding agencies (e.g. NIH, DOD, NSF, ACS) may apply. Applications must be received by the Office of Cancer Research

( by 5 PM, September 8th, 2020. Application guidelines and application packet are attached.

Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the Office of Cancer

Research staff at or call 405-271-1878.

URL: Guidelines-Fall-2020.pdf?ver=2020-07-13-101339-037


NEW CITI Course:  COVID-19: Back to Campus

AAMC and CITI Program have partnered to launch a complimentary course for staff, students, and faculty on safely returning to research

activities on campus.  This course is strictly voluntary for those wishing to have additional information about how to maintain a safe research

environment in the time of COVID-19.  This course was designed by AAMC and CITI and does not necessarily follow all of OUHSC

guidelines for return to work or return to research (which can be found here: 

Please be certain to review OUHSC policies if you have any questions.  You can access the course by following the instructions attached.

URL: Instructions for New COVID-19 Course.docx?ver=2020-07-06-081424-413


OMB M-20-26: Extension of Administrative Relief for Recipients and Applicants of Federal Financial Assistance (COVID-19)

a memo was published by OMB, extending certain of the flexibilities provided by M-20-17.






Oklahoma Covid-19 Working Group

Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the  OCTSI Website

( A list of investigators in the working group and their planned or ongoing projects are described.

A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to

have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of

Microbiology and Immunology, OUHSC ( ).



Oklahoma Shared Clinical and Translational Resources Clinical and Translational Research Pilot (CTRP) Grants

The purpose of the program is to provide funding for collaborative and/or multi-disciplinary clinical and translational pilot projects between

investigators of the OSCTR member institutions. The program seeks to support proposals designed to generate preliminary data that will result

in improved health and/or healthcare for citizens of Oklahoma and other IDeA states and enhance the competitiveness of the investigators for

future extramural funding. The program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas to

solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the medically underserved and on

health concerns prevalent within Oklahoma and our OSCTR partners will be a priority. Only projects which meet the NIH definition of clinical

and/or translational research will be accepted.

Approved CTRP grants will be funded for a period starting January 1, 2021 contingent on NIH approval of just in time (JIT) information.

All funds are required to be expended by December 31, 2021.

The forms, instructions, and submission link can be found at:

Deadlines for submission:   Pilot Proposal – Friday, August 7, 2020 at 5:00 PM CDT



Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards

This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research

development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments

in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other

OSCTR pilot research programs and/or external funding.

The application should consist of a 2-page letter from the main applicant (which can be either a community agency or an academic

researcher) describing the collaboration, the contributions that the proposed work will make to a successful research partnership, and

a line item budget. Budget requests are expected to be $5,000-$10,000 with budgets that permit the expenditure of the entire award by

June 30, 2021. A separate letter of support from either the academic or community partner indicating their agreement with the proposed

activities should also be included. Proposals will be evaluated on a rolling basis beginning July 1, 2020. Please submit proposals by

email to

Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the OSCTR staff

at or call 405-271-3480.



OU Office of Technology Commercialization presents a new opportunity to engage with industry (email or for specific submission details):

Provepharm Life Solutions is looking to engage with academia for developing novel small molecule-peptide conjugates with therapeutic

benefits (OUT OF SCOPE: antibody-drug conjugates, highly potent conjugates).  Non-confidential summary application

(200-300 word abstract) due August 3rd, 2020.

Example Projects:

  • Optimizing aspects relating to the conjugation of small molecules and peptides
  • Optimization to enhance overall functionality of small molecule-peptide conjugates
  • Fluorescence-guided surgery for immuno-oncology



The OU Medicine Laboratory is looking for equipment to assist with their COVID-19 testing.  Please see the attached list of

equipment needs. Please reply to if you have any of this equipment you could possibly loan.

URL: Ramp Up Ask List.docx?ver=2020-06-01-083246-413



OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the Testing supplies

listed in the attached “Testing Donations”.  Please return the complete form to

URL: Donations.xlsx?ver=2020-06-01-083249-427



OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the PPE supplies

listed in the attached “research PPE donation”.  The first line is an example of how to fill out the form.  Please return completed

form to

URL: Donations.xlsx?ver=2020-06-01-083249-427


Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:



Fast-Grants – Fast Funding for COVID-19 Science



NIH has created a central site for its current COVID-19 guidance at



OUHSC Financial Administrators:

The federal and state governments are asking that all institutions track their expenditures related to the COVID-19 pandemic. 

It is imperative that everyone is diligent in tracking all COVID-19 related expenditures for future reimbursement opportunities.  

Effective immediately, all COVID-19-related expenditures incurred since March 12 should be coded to a newly created COVID subclass.

These expenditures include, but are not limited to direct COVID-19 costs, increased housekeeping and maintenance costs, expenditures

related to business process modifications, preparatory actions, daily operations, and communications resulting from COVID-19.  If COVID

related expenses, since March 12, have already been paid, please process a cost transfer using the new COVID subclass. Research

faculty and staff should also track their expenditures incurred by the shutdown of their projects and laboratories including the loss of

samples, reagents, animals and other items.   Also, keep in mind that, asyou resume your activities in your lab, any expenses required

to restart the lab should be coded with the COVID subclass.  This will help significantly when applying for any administrative supplements

or other COVID-19 related relief efforts. Questions regarding the use of the subclass on non-research chartfields should be forwarded to and research related questions can be sent to



OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system related to COVID-19

please include “COVID-19” in the title so that we are able to search on it later.



COVID-19/Coronavirus Resources – a list from InfoEd



Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus

Disease 2019 (COV-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)





Grant and Contract Submission Requirements Regarding the Updated AVMA Guidelines for the Euthanasia of Animals: 2020 Edition



Pre-Application Webinar for RFA-CA-20-042, 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)



Notice to Extend the Response Date for NOT-MH-20-051, "Request for Information (RFI): Advancing Scientific and Workforce Diversity

in the BRAIN Initiative" (NOT-MH-20-071)


Notice of Expiration of PAR-20-178 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2

(SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)" (NOT-AI-20-062)


Notice of Expiration of PAR-20-177 "Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2

(SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)" (NOT-AI-20-063)


Notice to Extend NCCIH's PAR-18-417, Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research

Topics (R34, Clinical Trial Required) (NOT-AT-20-020)


Notice of Amendment of NCI Participation in PAR-20-164, Mechanisms and Consequences of Sleep Disparities in the U.S.

(R01 - Clinical Trial Not Allowed) (NOT-CA-20-075)


Notice to allow IDDRCs to put URLs in applications (NOT-HD-20-024)


Notice of Early Expiration of PAR-19-060 NINR Clinical Trial Planning Grant (R34 Clinical Trial Required)


Notice of Intent to Publish a Funding Opportunity Announcement for Superfund Hazardous Substance Research and Training Program

(P42 Clinical Trial Optional) (NOT-ES-20-021)


Extramural Loan Repayment Program for Clinical Researchers (LRP-CR) (NOT-OD-20-133)


Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB) (NOT-OD-20-134)


Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR)


Extramural Loan Repayment Program for Pediatric Research (LRP-PR) (NOT-OD-20-136)


Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR) (NOT-OD-20-137)


Notice of Special Interest: Epidemiology and Prevention in Alcohol Research (NOT-AA-20-017)


Notice of Special Interest: Notice of Availability of Funds for Administrative Supplements for Pediatric Radiation/Nuclear Animal Models,

MCM, Biodosimetry Development (NOT-AI-20-061)


Notice of Special Interest (NOSI): Methods Development in Natural Products Research (SBIR/STTR)


Notice of Special Interest (NOSI): Obesity Policy Evaluation Research (R01 Clinical Trial Not Allowed)


Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in

Air Pollution among High-Risk Populations (NOT-HL-20-788)



Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least two months prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.




PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications

(Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-20-260) – Deadline September 5, 2020 and January 5, 2021


PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications

(Parent STTR [R41/R42] Clinical Trial Required) (PA-20-261) – Deadlines September 5, 2020 and January 5, 2021


PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications

(Parent SBIR [R43/R44] Clinical Trial Required) (PA-20-262) – Deadline September 5, 2020 and January 5, 2021


PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications

(Parent STTR [R41/R42] Clinical Trial Not Allowed) (PA-20-265) – Deadline September 5 and January 5, 2021


Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related

Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (PAR-20-256)

Deadline on rolling basis beginning July 13, 2020


Promoting Research on Music and Health: Phased Innovation Award for Music Interventions

(R61/R33 Clinical Trial Optional) (PAR-20-266) - Deadline October 02, 2020 and June 02, 2021


NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) (PAR-20-267)
Deadilne September 25, 2020 and September 27, 2021


Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and

Responsiveness to Treatment (R01 Clinical Trial Optional) (PAR-20-269) – Deadline November 10, 2020


Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program

(R01 Clinical Trial Not Allowed) (RFA-CA-20-045) - Deadline December 16, 2020


BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)
(RFA-DA-21-006) - Deadline October 15, 2020 and October 14, 2021


Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical Trials Not Allowed

(RFA-DA-21-026) - Deadline November 13, 2020


NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)

(RFA-NS-21-001) - Deadline September 28, 2020 and September 28, 2021


NINDS Morris K. Udall Parkinson's Disease Research Center Without Walls (P20 Clinical Trial Optional)
(RFA-NS-21-002) - Deadline September 28, 2020